Operational & Sector-Specific

Biotech firm ProJenX reports its novel ALS drug, prosetin, is safe and hits key targets in early trials, offering a new beacon of hope for the disease.

A new silicon battery from Coreshell promises a 30% performance boost and a domestic supply chain, aiming to secure U.S. military technology from foreign risk.

A new partnership between Peak Nano and Advanced Conversion solves a key thermal challenge in high-voltage EVs, strengthening the US supply chain.

After shedding its past, BitVentures reports a stunning profit. But a deep dive reveals a one-time gain and a risky bet on e-commerce and crypto mining.

Edgewise Therapeutics unveils strong Phase 2 data for its HCM drug, EDG-7500, showing efficacy without the cardiac risks plaguing market leaders.

Soma Gold isn't just hiring; it's assembling a specialized team to execute an ambitious expansion, deepen its ESG commitment, and win the mining talent war.

Eastnets' new FCIP is more than a product launch; it's a strategic move against industry fragmentation, betting on explainable AI to unify risk.

Preliminary data from a randomized trial suggests a personalized medicine approach can reverse cognitive decline, offering a glimmer of hope beyond slowing the disease.

US innovator FlexPatio enters Australia's $48B reno market with a high-tech pergola. Is its DIY-friendly, storm-proof design the key to unlocking value?

A UK firm just put its radical compute engine on AWS, promising 500x speedups and 1000x less energy for finance and AI without major code rewrites.

A legacy sports giant just rewrote the playbook on tech adoption, deploying a new contact center in hours, not months. Here's what it signals about value and resilience.

International Petroleum Corp. celebrates a major win with its Blackrod project, delivering oil ahead of schedule. But the real story is in the data.

Marwest REIT's modest 2.1% distribution increase reveals deep financial stability in Western Canada's rental market, a stark contrast to national trends.

The FDA's approval of a new Type 1 Diabetes therapy is a landmark. But the real story is the collaborative engine clearing the path for future breakthroughs.

After 75 years, the Velan family has sold its controlling stake in the iconic valve maker. A deep dive into the C$204M deal and what it means for the future.

As biopharma navigates a maze of privacy laws and AI, a new platform aims to centralize patient consent, turning a compliance nightmare into a bridge for trust.

Wozoyo has launched with a promise to simplify our digital lives. Beyond the minimalist design, this is a calculated strategy from a veteran manufacturer.

Actiphy's new ImageReplicator strengthens cyber resilience with immutable backups and automated replication, shielding critical data from escalating ransomware threats.

Beyond a simple donation, Sysco's long-term partnership with Second Harvest reveals a strategic approach to tackling Canada's dual crises of hunger and waste.

Sharon AI and VAST Data are building a digital fortress. Their 600-petabyte deal isn't just about storage; it's a strategic move to forge a sovereign AI future for Australia.